Inoltre, potrebbero essere necessari pazienti pi anziani o quelli con pi condizioni mediche per iniziare una dose pi bassa per ridurre al minimo gli effetti collaterali
[DOI] [PubMed] [Google Scholar] 94.Muranaka H., Billet S., Cruz-Hernndez C., Hoeve J.T., Gonzales G., Elmadbouh O., Zhang L., Smith B., Tighiouart M., You S., et al
In addition, applying the 36.8% reduction in liver fibrosis without worsening of steatohepatitis observed with semaglutide 2.4 mg to the transition probabilities of fibrosis stages (F3) resulted in savings of 269,577,974, Table 1
The findings are based on pharmacy and medical claims data for about 170,000 people with insurance coverage under Blue Cross Blue Shield plans who were prescribed GLP-1 medications that were approved to treat weight management between 2014 and 2023
The pattern across the class is consistent: when weight, waist, insulin resistance, or liver fat returns, the lipid panel can drift back too